Clinical · Molecular biology
Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Summary
This study analyzed a cohort of 1,254 patients with biliary tract cancer to assess the utility of targeted NGS molecular profiling. It revealed that 59% of patients harbored at least one OncoKB alteration, and 32.2% had level 1/2 alterations, with varying frequencies across tumor locations. Targeted therapies were associated with improved progression-free survival but not overall survival. The study also identified co-occurring alterations and acquired resistance mechanisms, such as ERBB2 loss or alterations in the RAS, MEK, MET, MYC, and CDKN2A pathways. These findings highlight genomic heterogeneity and the importance of precision medicine in informing future drug development efforts.
Critical appraisal
**CLINIQUE:** This large-scale prospective cohort study (1,254 patients) utilizing an FDA-authorized targeted NGS assay demonstrates the real-world applicability of molecular profiling in biliary tract cancer. While targeted therapies improved progression-free survival, the lack of overall survival benefit suggests the need for a better understanding and overcoming of resistance mechanisms. The identification of co-occurring alterations (TP53/RAS, SMAD4) associated with inferior outcomes provides potential prognostic biomarkers that could guide patient stratification in future clinical trials. These data justify further phase II/III trials evaluating combination therapies or resistance-bypassing strategies, with a potential clinical impact within 3-5 years for treatment optimization.
**BIOMOL:** The study identified a significant proportion of actionable genomic alterations (59% OncoKB, 32.2% level 1/2) and emerging targets such as KRAS alterations (17%), MTAP deletions (12.8%), MDM2 amplification (6.5%), and MET amplification (1.5%). The use of an FDA-authorized targeted NGS assay ensures robust analytical validity. Longitudinal profiling characterized acquired resistance mechanisms, including ERBB2 loss in ERBB2-driven tumors and the emergence of alterations in RAS, MEK, MET, MYC, and CDKN2A genes. These molecular discoveries are crucial for the development of new targeted therapies addressing these resistance mechanisms and for designing clinical tests to monitor resistance biomarkers.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology